Optinose Stock Performance
| OPTN Stock | USD 0.54 0.04 8.00% |
The company holds a Beta of 1.55, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, OptiNose will likely underperform. At this point, OptiNose has a negative expected return of -0.74%. Please make sure to check OptiNose's maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if OptiNose performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days OptiNose has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | Disposition of 4881 shares by Mahmoud Ramy A of OptiNose at 0.87 subject to Rule 16b-3 | 09/17/2024 |
2 | Acquisition by Mahmoud Ramy A of 48907 shares of OptiNose subject to Rule 16b-3 | 09/26/2024 |
3 | OptiNose stock hits 52-week low at 0.68 amid market challenges - Investing.com | 09/30/2024 |
4 | OptiNose Inc Q2 2024 Earnings Call Highlights Revenue Growth and Strategic Shifts Amid ... | 10/09/2024 |
5 | Disposition of 1516 shares by Marino Michael F Iii of OptiNose at 1.15 subject to Rule 16b-3 | 11/01/2024 |
6 | OptiNose Inc Q3 2024 Earnings Report Preview What To Expect | 11/11/2024 |
7 | Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights | 11/12/2024 |
8 | OptiNose Inc Q3 2024 Earnings Call Highlights Revenue Growth Amid Revised Guidance | 11/13/2024 |
9 | Earnings Release Heres Why Analysts Cut Their OptiNose, Inc. Price Target To US3.50 | 11/15/2024 |
10 | Optinose to Announce Q3 2024 Financial Results with Investor Call - MSN | 11/20/2024 |
11 | Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference | 12/02/2024 |
| Begin Period Cash Flow | 94.2 M |
OptiNose |
OptiNose Relative Risk vs. Return Landscape
If you would invest 98.00 in OptiNose on September 5, 2024 and sell it today you would lose (44.00) from holding OptiNose or give up 44.9% of portfolio value over 90 days. OptiNose is currently does not generate positive expected returns and assumes 6.3879% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than OptiNose, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
OptiNose Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for OptiNose's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as OptiNose, and traders can use it to determine the average amount a OptiNose's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1153
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OPTN |
Estimated Market Risk
| 6.39 actual daily | 56 56% of assets are less volatile |
Expected Return
| -0.74 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average OptiNose is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of OptiNose by adding OptiNose to a well-diversified portfolio.
OptiNose Fundamentals Growth
OptiNose Stock prices reflect investors' perceptions of the future prospects and financial health of OptiNose, and OptiNose fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on OptiNose Stock performance.
| Return On Equity | -10.5 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | 125.64 M | ||||
| Shares Outstanding | 150.83 M | ||||
| Price To Earning | (3.41) X | ||||
| Price To Book | 24.26 X | ||||
| Price To Sales | 1.08 X | ||||
| Revenue | 70.99 M | ||||
| Gross Profit | 67.01 M | ||||
| EBITDA | (15.55 M) | ||||
| Net Income | (35.48 M) | ||||
| Cash And Equivalents | 78.26 M | ||||
| Cash Per Share | 0.94 X | ||||
| Total Debt | 130.23 M | ||||
| Current Ratio | 2.14 X | ||||
| Book Value Per Share | (0.24) X | ||||
| Cash Flow From Operations | (20.53 M) | ||||
| Earnings Per Share | (0.29) X | ||||
| Market Capitalization | 81.45 M | ||||
| Total Asset | 107.73 M | ||||
| Retained Earnings | (720.38 M) | ||||
| Working Capital | (71.19 M) | ||||
| Current Asset | 83.03 M | ||||
| Current Liabilities | 12.11 M | ||||
About OptiNose Performance
By examining OptiNose's fundamental ratios, stakeholders can obtain critical insights into OptiNose's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that OptiNose is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 340.44 | 323.41 | |
| Return On Tangible Assets | (0.33) | (0.35) | |
| Return On Capital Employed | 0.33 | 0.35 | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | 0.41 | 0.43 |
Things to note about OptiNose performance evaluation
Checking the ongoing alerts about OptiNose for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for OptiNose help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| OptiNose generated a negative expected return over the last 90 days | |
| OptiNose has high historical volatility and very poor performance | |
| OptiNose has some characteristics of a very speculative penny stock | |
| OptiNose has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 70.99 M. Net Loss for the year was (35.48 M) with profit before overhead, payroll, taxes, and interest of 67.01 M. | |
| OptiNose currently holds about 78.26 M in cash with (20.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| OptiNose has a frail financial position based on the latest SEC disclosures | |
| Over 78.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference |
- Analyzing OptiNose's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether OptiNose's stock is overvalued or undervalued compared to its peers.
- Examining OptiNose's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating OptiNose's management team can have a significant impact on its success or failure. Reviewing the track record and experience of OptiNose's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of OptiNose's stock. These opinions can provide insight into OptiNose's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OptiNose. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OptiNose. If investors know OptiNose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OptiNose listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Revenue Per Share 0.553 | Quarterly Revenue Growth 0.031 | Return On Assets (0.10) | Return On Equity (10.51) |
The market value of OptiNose is measured differently than its book value, which is the value of OptiNose that is recorded on the company's balance sheet. Investors also form their own opinion of OptiNose's value that differs from its market value or its book value, called intrinsic value, which is OptiNose's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OptiNose's market value can be influenced by many factors that don't directly affect OptiNose's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OptiNose's value and its price as these two are different measures arrived at by different means. Investors typically determine if OptiNose is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OptiNose's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.